MedPAC > Our Work > Drugs, Devices, and Tests > MedPAC comment on CMS’s proposed rule on contract year 2021 and 2022 policy and technical changes to Medicare Advantage and Part D
MedPAC comment on CMS’s proposed rule on contract year 2021 and 2022 policy and technical changes to Medicare Advantage and Part D